Skip to main content

Maria del Mar Riveiro Barciela

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria del Mar Riveiro Barciela

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Análisis de la interacción de los virus de la hepatitis B y D con el receptor del hepatocito y estudio prospectivo de la complejidad de sus quasiespecies virales

IP: Maria Buti Ferret
Collaborators: Lluís Viladomiu Catà, Maria del Mar Riveiro Barciela, Carolina Gonzalez Fernandez, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 147015
Reference: PI14/01416
Duration: 01/01/2015 - 31/12/2017

Estudio alegorizado de dos estrategias de tratamiento con Ribavirina para la Hepatitis Crónica E y formas agudas graves.

IP: Rafael Esteban Mur
Collaborators: Maria del Mar Riveiro Barciela, Francisco Rodríguez Frias, Josep Quer Sivila, Basilio Rodriguez Diez, Cristina Berastegui Garcia, Virginia Robles Alonso
Funding agency: Instituto de Salud Carlos III
Funding: 261360
Reference: ICI14/00367
Duration: 01/01/2015 - 30/06/2019

Malalties Hepatobiliars (GRC)

IP: Rafael Esteban Mur
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Victor Manuel Vargas Blasco, Maria Buti Ferret, Torrens Buscató, Maria Margarita, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Análisis de situación y estrategia de manejo de pacientes con infección crónica por VHB sin criterios de tratamiento según las guías de la Asociación Europea para el estudio del hígado

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela
Funding agency: GILEAD SCIENCES SLU
Funding: 39591
Reference: GLD13/00137
Duration: 18/09/2013 - 17/09/2014

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Albert Blanco Grau

Albert Blanco Grau

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Rubia Carpio, Maria del Mar

Rubia Carpio, Maria del Mar

Research assistant
Molecular Medical Imaging
Read more
Antonio Álvarez Fernandez

Antonio Álvarez Fernandez

Pneumology
Read more
Maceda Garcia, Almudena

Maceda Garcia, Almudena

Research technician
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.